The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Holding and bridging therapy selection in R/R aggressive B-cell lymphoma
Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, shares insights into the importance of bridging and holding therapy in patients with aggressive B-cell lymphoma, highlighting the need to differentiate between the two terms. Dr Iacoboni emphasizes that the goal of holding therapy is to avoid agents that can impact T-cell fitness, whereas bridging therapy aims to reduce tumor burden before CAR T-cell infusion. She recommends avoiding bendamustine prior to leukapheresis and highlights the safety of other agents, including CD20xCD3 bispecific antibodies. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
